Table 1.
Baseline characteristics
| Characteristic | Trimetazidine group | Placebo group | P-value |
|---|---|---|---|
| Sex (male:female) | 17:25 | 18:22 | 0.679 |
| Age (yr) | 41±10 | 45±9 | 0.088 |
| Tinnitus type | |||
| Hissing:ringing:total | 15:8:19 | 10:14:16 | 0.241 |
| Tinnitus laterality | |||
| Unilateral:bilateral | 25:17 | 21:19 | 0.522 |
| Pure tone average (dB HL) | |||
| Right | 26.1±3.7 | 24.8±3.0 | 0.072 |
| Left | 26.7±3.1 | 25.3±3.1 | 0.059 |
| TI duration (yr) | 6.4±2.2 | 5.6±1.6 | 0.234 |
| Global THI | 35.1±9.2 | 34.8±9.1 | 0.866 |
| Tinnitus loudness VAS (0–10) | 5.1±1.2 | 5.2±1.2 | 0.835 |
Values are presented as mean±SD.
HL, hearing loss; TI, tinnitus; THI, tinnitus handicap inventory; VAS, visual analogue scale.
THI=range 0–100, VAS=range 0–10. Pure tone average (500, 1,000, 2,000, 4,000, 8,000 Hz mean).